We therefore mapped the established signatures to lung cancer cell line data from the Broad Institute Cancer Cell Line Encyclopedia (CCLE)22 to determine which ones accurately measured oncogenic RAS activity in samples exempt of stroma and immune cells and where KRAS mutation is known to be a prevalent cancer driver. This evidence concerns the gene KRAS and lung cancer.